Kelly Martin to step down as Elan CEO in May 2012
This article was originally published in Scrip
Executive Summary
Kelly Martinis to step down as chief executive officer of Elan in May 2012, drawing a line under his often controversial tenure at the Irish company best known for its troubled multiple sclerosis drug Tysabri (natalizumab).